Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists

Abstract

Objective:

To review pharmacology, efficacy, safety, and considerations for use, of second-generation androgen receptor (AR) antagonists in treatment of nonmetastatic castrate-resistant prostate cancer (M0CRPC).

Data Sources:

Conducted search in PubMed and Google scholar (January, 1, 2002—December 31, 2022), using relevant terms.

Study Selection and Data Extraction:

Relevant English-language studies, conducted in humans evaluating second-generation AR antagonists for M0CRPC, and additional articles and package inserts were considered.

Data Synthesis:

Apalutamide, darolutamide, and enzalutamide are effective in delaying the time to development of metastatic prostate cancer in men with M0CRPC with a rapid prostate-specific antigen (PSA) doubling time (<10 months). No head-to-head, randomized, clinical trials have been conducted. The most common adverse effects include fatigue and hypertension, and quality of life is maintained in most patients. Cost is similar among the agents (~$15,000/month). Drug-drug interactions vary among these agents and should be considered, when selecting therapy as well as likely adherence. Darolutamide is administered twice daily with the others once daily.

Relevance to Patient Care and Clinical Practice:

Second-generation AR antagonists are effective in reducing time to development of metastatic disease and prolonging overall survival in patients with M0CRPC and a PSA doubling time of <10 months. Recent imaging advances may alter how we evaluate outcomes.

Conclusions:

Second-generation AR antagonists improve disease control and overall survival. Generally, they are well tolerated and QOL is maintained. Selection of the best agent is based on the adverse effect profile, potential for drug- and disease-interactions, administration, cost, and patient preference.

Keywords

castrate-resistant antiandrogen prostate cancer androgen deprivation therapy nonmetastatic

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Fuchs

Jemal

. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33. doi:10.3322/caac.21708

Etzioni

Tsodikov

Mariotto

, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-181. doi:10.1007/s10552-007-9083-8

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate cancer version 1.2023. Date unknown. Accessed November 13, 2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Huggins

Stevens

Jr Hodges

. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-223. doi:10.1001/archsurg.1941.01210140043004

Luo

Beer

Graff

. Treatment of nonmetastatic castration-resistant prostate cancer. Oncology. 2016;30(4):366-344.

Mateo

Fizazi

Gillessen

, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019;75(2):285-293. doi:10.1016/j.eururo.2018.07.035

Scher

Solo

Valant

Todd

Mehra

. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS ONE. 2015;10(10):e0139440. doi:10.1371/journal.pone.0139440

Smith

Kabbinavar

Saad

, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23(13):2918-2925. doi:10.1200/JCO.2005.01.529

Beer

Armstrong

Rathkopf

, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Eng J Med. 2014;371(5):424-433. doi:10.1056/NEJMoa1405095

10.

Afshar

Evison

James

Patel

. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience. Urol Oncol. 2015;33(8):338e1-338e7. doi:10.1016/j.urolonc.2015.05.003

11.

US Food and Drug Administration. Hematology/oncology (cancer) approvals & safety notifications. Date unknown. Accessed October 26, 2022. https://wayback.archive-it.org/7993/20201219232235/https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications

12.

Smith

Saad

Oudard

, et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31(30):3800-3806. doi:10.1200/JCO.2012.44.6716

13.

Howard

Moreira

De Hoedt

, et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017;120(5B):E80-E86. doi:10.1111/bju.13856

14.

Mohler

Gregory

Ford

III , et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;15(10):440-448. doi:10.1158/1078-0432.ccr-1146-03

15.

Montgomery

Mostaghel

Vessella

, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447-4454. doi:10.1158/0008-5472.CAN-08-0249

16.

Scher

Sawyers

. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253-8261. doi:10.1200/JCO.2005.03.4777

17.

Small

Saad

Chowdhury

, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019;30:1813-1820. doi:10.1093/annonc/mdz397

18.

Shamash

Powles

Sarker

, et al. A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred diethylstilbestrol. Br J Cancer. 2011;104:620-628. doi:10.1038/bjc.2011.7

19.

Clegg

Wongvipat

Joseph

, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-1503. doi:10.1158/0008-5472.CAN-11-3948

20.

Smith

Saad

Chowdhury

, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Eng J Med. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546

21.

Smith

Saad

Chowdhury

, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150-158. doi:10.1016/j.eururo.2020.08.011

22.

Hussain

Fizazi

Saad

, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465-2474. doi:10.1056/NEJMoa1800536

23.

Sternberg

Fizazi

Saad

, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197-2206. doi:10.1056/NEJMoa2003892

24.

Fizazi

Smith

Tombal

. Clinical development of darolutamide: a novel androgen receptor antagonist for treatment of prostate cancer. Clin Genit Cancer. 2018;16:332-340. doi:10.1016/j.clgc.2018.07.017

25.

Moilanen

Riikonen

Oksala

, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5(1):1-11. doi:10.1038/srep12007

26.

Abbasi

Movahedpour

Amiri

Najaf

Mostafavi-Pour

. Darolutamide as a second-generation androgen receptor inhibitor in the treatment of prostate cancer. Curr Mol Med. 2021;21(4):332-346. doi:10.2174/1566524020666200903120344

27.

Fizazi

Albiges

Loriot

Massard

. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015;15(9):1007-1017. doi:10.1586/14737140.2015.1081566

28.

Fizazi

Shore

Tammela

, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Eng J Med. 2019;380(13):1235-1246. doi:10.1056/NEJMoa1815671

29.

Fizazi

Shore

Tammela

. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040-1049. doi:10.1056/NEHMoa2001342

30.

Vidal

Gomez Rivas

Fernandez

Moreno

Puente

. The past, present, and future of non-metastatic castration-resistant prostate cancer (nmCRPC): a narrative review. Precis Cancer Med. 2022;5:14. doi:10.21037/pcm-21-34

31.

Small

Halabi

Dawson

, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025-1033. doi:10.1200/JCO.2004.06.037

32.

Erleada (apalutamide) [package insert]. Janssen Products, Inc; 2022.

33.

Chen

Zhou

Hankey

Fang

Yuan

. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022;13:632. doi:10.1038/s41419-022-05084-1

34.

Zurth

Sandmann

Trummel

Seidel

Gieschen

. Blood-brain barrier penetration of [14C] darolutamide compared with [14C] enzalutamide in rats using whole body autoradiography. J Clin Oncol. 2018;36(suppl 6):345.

35.

Xtandi (enzalutamide) [package insert]. Pfizer, Inc.; 2022.

36.

Nubeqa (darolutamide) [package insert]. Bayer HealthCare Pharmacueticals, Inc.; 2022.

37.

Conde-Estévez

Henríquez

Muñoz-Rodríguez

Rodriguez-Vida

. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2022;18(9):601-613. doi:10.1080/17425255.2022.2122812

38.

Pollock

Smith

Saad

, et al. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide [published online ahead of print October 8, 2022]. Prostate Cancer Prost Dis. doi:10.1038/s41391-022-00592-9

39.

Oudard

Hadaschik

Saad

, et al. Health-related quality of life at the SPARTAN final analysis of apalutamide for nonmetastatic castration-resistant prostate cancer patients receiving androgen deprivation therapy. Eur Urol Focus. 2022;8(4):958-967. doi:10.1016/j.euf.2021.08.005

40.

Tombal

Saad

Penson

, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicenter, randomized, double-blind, phase 3 study. Lancet. 2019;20:556-569. doi:10.1016/S1470-2045(18)30898-2

41.

Smith

Shore

Tammela

, et al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021;154:138-146. doi:10.1016/j.ejca.2021.06.010

42.

Lexi-Drugs. Lexicomp. Published 2022. Accessed November 13, 2022. http://online.lexi.com/

43.

Shore

Jiang

Garcia-Horton

, et al. The hospitalization-related costs of adverse events for novel androgen-receptor inhibitors in non-metastatic castration-resistant prostate cancer: an indirect comparison. Adv Ther. 2022;39(11):5025-5042. doi:10.1007/s12325-022-02245-8

44.

De Visschere

PJL

Standaert

Fütterer

, et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol. 2019;2(1):47-76. doi:10.1016/j.euo.2018.09.010

45.

Ghafoor

Burger

Vargas

. Multimodality imaging of prostate cancer. J Nucl Med. 2019;60(10):1350-1358. doi:10.2967/jnumed.119.228320

46.

Tsechelidis

Vrachimis

. PSMA PET in imaging prostate cancer. Front Oncol. 2022;12:831429. doi:10.3389/fonc.2022.831429

47.

Caracciolo

Castello

Urso

, et al. The role of [68Ga] PSMA PET/CT for clinical suspicion of prostate cancer in patients with or without previous negative biopsy: a systematic review. Cancers (Basel). 2022;14:4036. doi:10.3390/cancers14205036

48.

McKay

Feng

Wang

Wallis

CJD

Moses

. Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions. Am Soc Clin Oncol Educ Book. 2020;40:1-12. doi:10.1200/ EDBK_279459

49.

Mollica

Rizzo

Rosellini

, et al. Bone targeting agents in patients with metastatic prostate cancer: state of the art. Cancers. 2021;13:546. doi:10.3390/cancers13030546

50.

Rossellini

Santoni

Mollica

, et al. Treating prostate cancer by antibody-drug conjugates. Int J Mol Sci. 2021;22:1551. doi:10.3390/ijms22041551

51.

Rizzo

Mollica

Cimadamore

, et al. Is there a role for immunotherapy in prostate cancer? Cells. 2020;9:2051. doi:10/3390/cells9092051